Verily, Kyverna Therapeutics forge collaboration for autoimmune research
Verily, an Alphabet precision health technology company, and Kyverna Therapeutics, a clinical-stage cell therapy company, have announced a multi-year collaboration. The initial focus is on deploying Verily’s advanced Immune Profiler to identify treatment-response biomarkers in autoimmune patients undergoing Phase 1 clinical trials for Kyverna’s KYV-101 in the US and Europe. Unveiling the Biological Basis of […]